# Risedronic Acid

## Reosteo 150mg

| 藥物代碼 | OREOS |
| :--- | :--- |
| 適應症 | Treatment of osteoporosis in postmenopausal women to increase bone mass & reduce incidence of fractures, including those of the hip & spine \(vertebral compression fractures\). Treatment of osteoporosis in men to increase bone mass. |
| 副作用 | CommonDermatologic: Rash \(osteoporosis, 7.9%; Paget disease, 11.5% \)Gastrointestinal: Abdominal pain \(osteoporosis, 2.9% to 12.2% ; Paget disease, 11.5% \), Constipation \(osteoporosis, 2.9% to 12.9% ; osteoporosis prevention, 6.5%; Paget disease, 6.6% \), Diarrhea \(osteoporosis, 4.9% to 10.8% ; Paget disease, 19.7% \), Indigestion \(3.9% to 10.8% \), Nausea \(osteoporosis, 3.6% to 3.9% ; osteoporosis prevention, 7.3% to 13.2% ; Paget disease, 9.8% \)Musculoskeletal: Backache \(adult, 5.9% to 28% ; pediatric, 17% \)Renal: Urinary tract infectious disease \(11.1% \)Other: Influenza-like illness \(up to 9.8% \)SeriousCardiovascular: Cardiac dysrhythmia \(men, 2% \), Peripheral edema \(8.2% \)Dermatologic: Hypersensitivity reactionMusculoskeletal: Arthralgia \(osteoporosis, 6.8% to 24.7% ; osteoporosis prevention, 13.9%; Paget disease, 32.8% \), Bone pain \(adult, 5.3%; acute phase reaction, 1.1% to 7.6%; pediatric, 10% \), Myalgia \(1% to 6.7% ; osteoporosis prevention, 5.1% \), Osteonecrosis of jawOphthalmic: Iritis, UveitisRenal: Nephrolithiasis \(3% \)Reproductive: Benign prostatic hyperplasia \(5% \) |
| 禁忌 | Esophageal abnormalities \(eg, stricture or achalasia\) that delay esophageal emptying. Hypersensitivity to risedronate or any component of the product. Inability to sit or stand upright for at least 30 minutes. Hypocalcemia. |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | \[仿單\]未有相關紀載 |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | \[仿單\]未有相關紀載 |
| 注射劑給藥建議途徑 | AC |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

